Proceeds to strengthen financial position and fund growth initiatives
By Melissa Kory
Cleveland, Jan. 13 - NeoGenomics, Inc. settled a $3,002,500.50 private placement of shares on Jan. 12, according to an 8-K filed Thursday with the Securities and Exchange Commission and a company news release.
The company sold 2,001,667 shares of the company's common stock at $1.50 per share. The price was a 9.5% premium to the company's closing stock price of $1.37 on Jan. 12.
The investors include, among others, the Douglas M. VanOort Living Trust, which chief executive officer and chairman of the company's board of directors Douglas VanOort is affiliated with; the Steven and Carisa Jones Defined Benefit Pension Plan & Trust, which executive vice president of finance and director Steven Jones is affiliated with; the George A. Cardoza Family Trust, which chief financial officer George Cardoza is affiliated with; vice president of sales and marketing Mark W. Smits; and director Kevin C. Johnson.
The company plans to use the proceeds to strengthen its financial position and fund growth initiatives.
Based in Fort Myers, Fla., NeoGenomics is a cancer genetics diagnostics testing company.
| Issuer: | NeoGenomics, Inc.
|
| Issue: | Common Stock
|
| Amount: | $3,002,500.50
|
| Shares: | 2,001,667
|
| Price: | $1.50
|
| Warrants: | No
|
| Settlement date: | Jan. 12
|
| Stock symbol: | OTCBB: NGNM
|
| Stock price: | $1.37 at close Jan. 12
|
| Market capitalization: | $56.11 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
